Tvardi Therapeutics, Inc. (TVRD)
US — Healthcare Sector
Peers:
Automate Your Wheel Strategy on TVRD
With Tiblio's Option Bot, you can configure your own wheel strategy including TVRD - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol TVRD
- Rev/Share 0.7979
- Book/Share 3.9928
- PB 8.9824
- Debt/Equity 0.0077
- CurrentRatio 4.0391
- ROIC -0.6967
- MktCap 336287670.0
- FreeCF/Share -3.83
- PFCF -10.6474
- PE -14.1554
- Debt/Assets 0.0058
- DivYield 0
- ROE 1.435
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | TVRD | Raymond James | -- | Outperform | -- | $62 | July 14, 2025 |
| Initiation | TVRD | Cantor Fitzgerald | -- | Overweight | -- | $52 | July 11, 2025 |
| Initiation | TVRD | Piper Sandler | -- | Overweight | -- | $78 | June 12, 2025 |
| Initiation | TVRD | Oppenheimer | -- | Outperform | -- | $65 | May 21, 2025 |
| Initiation | TVRD | BTIG Research | -- | Buy | -- | $55 | May 15, 2025 |
News
About Tvardi Therapeutics, Inc. (TVRD)
- IPO Date 2025-04-16
- Website https://tvarditherapeutics.com BioSpace +4
- Industry Biotechnology
- CEO Imran Alibhai
- Employees 17
Tvardi Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need. Their lead candidate, TTI-101, is currently in Phase 2 clinical trials for idiopathic pulmonary fibrosis (IPF) and hepatocellular carcinoma (HCC).